1. Scrip
  2. >>Business
  3. >>Strategy

Amgen Building On Repatha Experience As It Grows In Cardiovascular, Obesity

Execs Shared Strategy At J.P. Morgan Meeting

 
• By Mandy Jackson

Repatha was not an overnight success, but the work Amgen has done to turn its PCSK9 inhibitor into a blockbuster is informing its strategy for Lp(a)-reducing olpasiran and obesity drug MariTide.

Amgen has invested millions in physician and patient education already in support of Repatha (Shutterstock)

Amgen is no stranger to the heavy lifting required to get a new treatment for cardiovascular diseases off the ground, since its LDL cholesterol-lowering PCSK9 inhibitor Repatha (evolocumab) was not an immediate blockbuster. But now that the drug is annualizing at more than $2bn in sales, the company will use the commercialization muscles it developed for Repatha to build its strategies for Lipoprotein(a)-reducing olpasiran and obesity candidate maridebart cafraglutide (MariTide, formerly AMG 133).

Key Takeaways
  • Amgen’s experience with PCSK9 inhibitor Repatha’s development as an LDL cholesterol-lowering treatment has informed the company’s planned cardiovascular disease growth strategy.
  • The...

CEO Robert Bradway highlighted Repatha, olpasiran and MariTide during his J.P. Morgan Healthcare Conference presentation on 13 January and Amgen executives discussed the company’s strategy for the product and new...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By Joseph Haas

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

More from Market Access

AbbVie On MFN: ‘We Have To Take It Seriously’

 
• By Jessica Merrill

AbbVie chief commercial officer Jeffrey Stewart called Trump’s drug pricing plan a “disruption” but said ultimately the delta between US and EU drug prices may not be as high as some expect.

Industry Leaders Grapple With Trump’s MFN Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on what Trump’s executive order on drug pricing could mean for US and European drug prices.

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.